RFP - supply of a first line enzyme replacement therapy for the treatment of Gaucher disease - AMENDED 10 AUGUST 2017
PHARMAC invites proposals for the supply of a first line enzyme replacement therapy for the treatment of Gaucher disease.
We would draw your attention to an amendment to the subsidy/price of imiglucerase, inj 40 iu per ml, 400 iu vial in the Pharmaceutical Schedule listing table in Schedule 1, paragraph 3 of the RFP as follows (deletions shown by
strikethrough, additions shown in bold):
The table below outlines the current Pharmaceutical Schedule listing of Imiglucerase (Cerezyme) in the Gaucher’s Disease section of the Metabolic Disorder Agents sub-group of the Alimentary Tract and Metabolism Therapeutic Group Section B of the Pharmaceutical Schedule.
IMIGLUCERASE Special Authority see SA0473 below – Retail pharmacy
Brand or Generic Manufacturer
|Inj 40 iu per ml, 200 iu vial||1,072.00||1||Yes||Cerezyme|
|Inj 40 iu per ml, 400 iu vial||1||Yes||Cerezyme|
This request for proposals (RFP) letter incorporates the following schedules:
- Schedule 1 specifies the pharmaceutical for which PHARMAC is requesting proposals and sets out the background to the RFP and the types of proposals sought;
- Schedule 2 describes the process that PHARMAC expects to follow in relation to the RFP;
- Schedule 3 sets out information about the estimated size of the current subsidised market for the pharmaceutical; and
- Schedule 4 [DOC, 104 KB] contains the RFP form in which you are to provide details of your proposal.
Full text of RFP - supply of a first line enzyme replacement therapy for Gaucher disease (AMENDED 10 AUGUST 2017) [PDF, 231 KB]
If you wish to submit a proposal, please submit it to PHARMAC via the Government Electronic Tenders Service (GETS) (www.gets.govt.nz(external link)) no later than 4.00 p.m. on Friday 8 September 2017 - RFx 18880393.
If you have any inquiries about this RFP you should submit them via GETS or alternatively contact Matthew Wolfenden, Procurement Manager, by email firstname.lastname@example.org. Answers to questions will be provided through GETS. PHARMAC will also post any addenda through GETS. We encourage interested suppliers to register with GETS and subscribe to this RFP to be kept up to date.
We look forward to receiving your proposal.